Anti-diabetes therapy: Safety considerations for patients with impaired kidney function

Janet B. Mcgill

doi:10.3810/pgm.2014.05.2765

Anti-diabetes therapy: Safety considerations for patients with impaired kidney function

Janet B. Mcgill

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The presence of type 2 diabetes mellitus (T2DM) is a common risk factor for the development of chronic kidney disease, but appropriate glycemic control can slow the progression of kidney dysfunction in patients with T2DM. The kidney plays a role in insulin resistance and gluconeogenesis, therefore, impaired kidney function alters glucose dynamics compared with normal kidney function, thus affecting antihyperglycemic treatment strategies. Glycemic management is further complicated by reduced drug clearance and a greater risk of hypoglycemia with use of certain medications, notably the sulfonylureas. Of the classes of antihyperglycemic drugs discussed in this review, caution is advised when using some classes in patients with T2DM and kidney disease.

Original language	English
Pages (from-to)	161-171
Number of pages	11
Journal	Postgraduate medicine
Volume	126
Issue number	3
DOIs	https://doi.org/10.3810/pgm.2014.05.2765
State	Published - Jan 1 2014

Keywords

Chronic kidney disease
Clinical management
Incretin therapy
Type 2 diabetes mellitus

Access to Document

10.3810/pgm.2014.05.2765

Cite this

@article{ff937dc525154cf1b01b8bfa79b84692,

title = "Anti-diabetes therapy: Safety considerations for patients with impaired kidney function",

abstract = "The presence of type 2 diabetes mellitus (T2DM) is a common risk factor for the development of chronic kidney disease, but appropriate glycemic control can slow the progression of kidney dysfunction in patients with T2DM. The kidney plays a role in insulin resistance and gluconeogenesis, therefore, impaired kidney function alters glucose dynamics compared with normal kidney function, thus affecting antihyperglycemic treatment strategies. Glycemic management is further complicated by reduced drug clearance and a greater risk of hypoglycemia with use of certain medications, notably the sulfonylureas. Of the classes of antihyperglycemic drugs discussed in this review, caution is advised when using some classes in patients with T2DM and kidney disease.",

keywords = "Chronic kidney disease, Clinical management, Incretin therapy, Type 2 diabetes mellitus",

author = "Mcgill, \{Janet B.\}",

note = "Funding Information: Medical writing support for the preparation of this manuscript was provided by Valerie P. Zediak, PhD, and Judy Fallon, PharmD, CMPP, from Complete Healthcare Communications, Inc. (Chadds Ford, PA), with funding from Bristol-Myers Squibb and AstraZeneca LP. Publisher Copyright: {\textcopyright} Postgraduate Medicine.",

year = "2014",

month = jan,

day = "1",

doi = "10.3810/pgm.2014.05.2765",

language = "English",

volume = "126",

pages = "161--171",

journal = "Postgraduate medicine",

issn = "0032-5481",

number = "3",

}

TY - JOUR

T1 - Anti-diabetes therapy

T2 - Safety considerations for patients with impaired kidney function

AU - Mcgill, Janet B.

N1 - Funding Information: Medical writing support for the preparation of this manuscript was provided by Valerie P. Zediak, PhD, and Judy Fallon, PharmD, CMPP, from Complete Healthcare Communications, Inc. (Chadds Ford, PA), with funding from Bristol-Myers Squibb and AstraZeneca LP. Publisher Copyright: © Postgraduate Medicine.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The presence of type 2 diabetes mellitus (T2DM) is a common risk factor for the development of chronic kidney disease, but appropriate glycemic control can slow the progression of kidney dysfunction in patients with T2DM. The kidney plays a role in insulin resistance and gluconeogenesis, therefore, impaired kidney function alters glucose dynamics compared with normal kidney function, thus affecting antihyperglycemic treatment strategies. Glycemic management is further complicated by reduced drug clearance and a greater risk of hypoglycemia with use of certain medications, notably the sulfonylureas. Of the classes of antihyperglycemic drugs discussed in this review, caution is advised when using some classes in patients with T2DM and kidney disease.

AB - The presence of type 2 diabetes mellitus (T2DM) is a common risk factor for the development of chronic kidney disease, but appropriate glycemic control can slow the progression of kidney dysfunction in patients with T2DM. The kidney plays a role in insulin resistance and gluconeogenesis, therefore, impaired kidney function alters glucose dynamics compared with normal kidney function, thus affecting antihyperglycemic treatment strategies. Glycemic management is further complicated by reduced drug clearance and a greater risk of hypoglycemia with use of certain medications, notably the sulfonylureas. Of the classes of antihyperglycemic drugs discussed in this review, caution is advised when using some classes in patients with T2DM and kidney disease.

KW - Chronic kidney disease

KW - Clinical management

KW - Incretin therapy

KW - Type 2 diabetes mellitus

UR - https://www.scopus.com/pages/publications/84906926149

U2 - 10.3810/pgm.2014.05.2765

DO - 10.3810/pgm.2014.05.2765

M3 - Article

C2 - 24918801

AN - SCOPUS:84906926149

SN - 0032-5481

VL - 126

SP - 161

EP - 171

JO - Postgraduate medicine

JF - Postgraduate medicine

IS - 3

ER -

Anti-diabetes therapy: Safety considerations for patients with impaired kidney function

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this